Kleoniki Roka

Dr. Kleoniki Roka

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2014 in Helicobacter
Verified
Journal Article
Closed access
PDF file
Kleoniki RokaKleoniki Roka
Kleoniki Roka
ARAikaterini Roubani
Aikaterini Roubani
KSKalliopi Stefanaki
Kalliopi Stefanaki
IPIoanna Panayotou
Ioanna Panayotou
EREleftheria Roma
Eleftheria Roma
GCGeorge Chouliaras
George Chouliaras

1 November 2013 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
Kleoniki RokaKleoniki Roka
Kleoniki Roka
EREleftheria Roma
Eleftheria Roma
KSKalliopi Stefanaki
Kalliopi Stefanaki
IPIoanna Panayotou
Ioanna Panayotou
GKGiannis Kopsidas
Giannis Kopsidas
GCGiorgos Chouliaras
Giorgos Chouliaras
Focally enhanced gastritis (FEG) has been suggested as a diagnostic marker for patients with Crohn's disease. In this study we evaluated the prevalence of FEG in children with inflammatory bowel diseases (IBD) and assessed the ability of FEG to distinguish IBD from non-IBD patients. A retrospective study of the children who underwent esophagogastroduodenal endoscopy (EGD) during 2004-2011 was performed, after excluding individuals with H. pylori infection and celiac disease. Two groups were studied: patients with IBD (IBD group, n=185) and non-IBD patients who underwent endoscopy of the upper gastrointestinal tract for various abdominal complaints (non-IBD group, n=684). Relation of FEG to age and gender was also assessed. FEG was found significantly more frequently among children with IBD (35.7% vs 3.4%, respectively, p<0.001). Children with FEG were 15.4 times more likely to have IBD than to belong in the non-IBD group. All types of IBD had significantly higher frequencies of FEG compared to non-IBD individuals (Crohn's disease: 54.1%, ulcerative colitis: 21.6%, IBD unclassified: 18.4%, all three comparisons with the non-IBD group: p-values<0.001). FEG positivity was more common in females compared to males with Crohn's disease and ulcerative colitis and in children younger than 2 years in the IBD-unspecified group. FEG achieved a sensitivity of 35.7% and specificity of 96.6% in distinguishing between IBD from non-IBD patients. FEG has significantly higher prevalence in children with IBD, particularly Crohn's disease and can be a valuable supporting finding in cases of indefinite diagnosis.

19 May 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
Kleoniki RokaKleoniki Roka
Kleoniki Roka
ESElena E. Solomou
Elena E. Solomou
AKAntonis Kattamis
Antonis Kattamis
Variations in the length of telomeres and pathogenic variants involved in telomere length maintenance have been correlated with several human diseases. Recent breakthroughs in telomere biology knowledge have contributed to the identification of illnesses named “telomeropathies” and revealed an association between telomere length and disease outcome. This review emphasizes the biology and physiology aspects of telomeres and describes prototype diseases in which telomeres are implicated in their pathophysiology. We also provide information on the role of telomeres in hematological diseases ranging from bone marrow failure syndromes to acute and chronic leukemias.

12 September 2019 in Postgraduate Medicine
Verified
Journal Article
Closed access
EKEleftheria Kokkinou
Eleftheria Kokkinou
Kleoniki RokaKleoniki Roka
Kleoniki Roka
AAAlexis Alexopoulos
Alexis Alexopoulos
ETEfthymia Tsina
Efthymia Tsina
INIoannis Nikas
Ioannis Nikas
RPRoser Pons
Roser Pons
Given the complexity of neurocutaneous syndromes, a multidisciplinary approach has been advocated in order to provide optimum care. Subjects and Methods: Retrospective analysis of a cohort of 157 patients during a 3-year period, seen at a newly developed neurocutaneous clinic in a pediatric tertiary care hospital in Athens (Greece); and systematic chart review of the patients diagnosed with neurofibromatosis type 1 during this time period. Results: The most frequent neurocutaneous syndromes were neurofibromatosis type 1 (NF1) in 89 patients and tuberous sclerosis complex in 17. In 20.38% of patients a neurocutaneous syndrome was not confirmed. Approximately 2/3 of the NF1 patients underwent genetic analysis, and for 76.67% of them, a pathogenic mutation on the NF1 gene was revealed. Eighty-one patients manifested with generalized NF1 and eight with mosaic NF1. Dermatological manifestations included café-au-lait macules in all patients, followed by axillary and/or inguinal freckling (n = 57), external plexiform neurofibromas (n = 17), and cutaneous and subcutaneous neurofibromas (n = 11). Approximately half of patients had learning disabilities and attention deficit hyperactivity disorder, followed by mental retardation (n = 9), autistic spectrum disorders (n = 4), headaches (n = 3) and seizures (n = 2). Neuroimaging showed characteristic areas of hyperintensity on T2-weighted images in 74.07% of patients and optic pathway glioma in 19.75%. Two patients developed malignant peripheral sheath nerve tumor. Conclusions: Neurocutaneous syndromes are clinically heterogeneous and the surveillance of potential clinical complications is challenging. The availability of genetic diagnosis and novel imaging methods in this group of disorders is likely to further expand their clinical spectrum. Guidelines for assessment and management will need to be modified based on new available data.

7 May 2010 in Helicobacter
Verified
Journal Article
Closed access
PDF file
EREleftheria Roma‐Giannikou
Eleftheria Roma‐Giannikou
ARAlkaterini Roubani
Alkaterini Roubani
Dionyssios Nicholas SgourasDionyssios Nicholas Sgouras
Dionyssios Nicholas Sgouras
JPJoanna Panayiotou
Joanna Panayiotou
CVCatherine Van‐Vliet
Catherine Van‐Vliet
GDGeorge Daikos
George Daikos

8 May 2024 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
GNGunther Nussbaumer
Gunther Nussbaumer
MBMartin Benesch
Martin Benesch
YGYura Grabovska
Yura Grabovska
AMAlan Mackay
Alan Mackay
DCDavid Castel
David Castel
CKChristof Maria Kramm
Christof Maria Kramm
The term Gliomatosis cerebri (GC), a radiology-defined highly infiltrating diffuse glioma, has been abandoned since molecular GC-associated features have not been established yet. We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive clinical and (epi-)genetic characterization. Median overall survival (OS) was 15.5 months (interquartile range, 10.9–27.7) with a 2-years survival rate of 28%. Histopathological grading correlated significantly with median OS: CNS WHO grade II: 47.8 months (25.2–55.7); grade III: 15.9 months (11.4–26.3); grade IV: 10.4 months (8.8–14.4). By DNA methylation profiling (n=49), most tumors were classified as pediatric-type diffuse high-grade glioma (pedHGG), H3-/IDH-wildtype (n=31/49, 63.3%) with enriched subclasses pedHGG_RTK2 (n=19), pedHGG_A/B (n=6), and pedHGG_MYCN (n=5), but only one pedHGG_RTK1 case. Within the pedHGG, H3-/IDH-wildtype subgroup, recurrent alterations in EGFR (n=10) and BCOR (n=9) were identified. Additionally, we observed structural aberrations in chromosome 6 in 16/49 tumors (32.7%) across tumor types. In the pedHGG, H3-/IDH-wildtype subgroup TP53 alterations had a significant negative effect on OS. Contrary to previous studies, our representative pediatric GC study provides evidence that GC has a strong predilection to arise on the background of specific molecular features (especially pedHGG_RTK2, pedHGG_A/B, EGFR and BCOR mutations, chromosome 6 rearrangements).